Galapagos NV
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
26 jan 2016 - 07:30
Statutaire naam
Galapagos NV
Titel
Galapagos reports results with GLPG1205 in ulcerative colitis
Bericht
Phase 2a study confirms good pharmacokinetics, safety and tolerability
In ulcerative colitis patients, primary endpoint for efficacy was not met
Mechelen, Belgium; 26 January 2016; 7.30 CET - Galapagos NV (Euronext & NASDAQ: GLPG) announced today that the ORIGIN Phase 2a study with GLPG1205 confirmed good pharmacokinetics, safety and tolerability. The endpoints for efficacy of GLPG1205 in patients with ulcerative colitis (UC), however, were not met. Galapagos will discontinue clinical development in UC.
Gerelateerde downloads
Datum laatste update: 19 december 2025